perspectiva aiqbenchProduse AI

The article focuses on applying AI techniques to optimize the traditionally inefficient process of pharmaceutical development, specifically addressing cost reduction and speed in target identification. By leveraging machine learning models, companies aim to break Eroom's Law through a closed-loop data system that accelerates clinical trial success rates. This represents a significant shift from traditional methods toward algorithmic efficiency in high-stakes biological research.

Sursă care acoperăMIT Technology Review

Ce este aceastaLectura unui model asupra articolului și a acoperirii conexe, scrisă pentru aiqbench. Nu sunt cuvintele publicației.

Closing the data loop in AI-driven drug discovery

MIT Technology Review27 iulie 20261 min de cititArticolul și perspectiva sunt în engleză.

Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law. Today, bringing a new drug to market takes an average of 10-15 years and costs…

Citește articolul complet pe MIT Technology Review

Citește pe MIT Technology Review ↗Întreabă despre acest articol